With CEA-positive human pharyngeal carcinoma cell line Detrioit562 and HER2-positive human NSCLC cell line H292 as target cells, immune cells modified by both CAR constructs exerted dose-dependent, cytotoxic effects on tumor cells, whereas CAR-modified CIKZ cells displayed killing efficacy relatively higher or comparable to CAR-modified αβ T cells (Fig 5D). This evidence concerns the gene ERBB2 and carcinoma of pharynx.